Posted: Monday, September 23, 2019
Andreas Rimner, MD, of Memorial Sloan Kettering Cancer Center, discusses how consolidation therapy with durvalumab is changing the pattern of disease recurrence in patients treated for stage III non–small cell lung cancer.